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Dopamine contributes to corticostriatal plasticity
and motor learning. Dopamine denervation
profoundly alters motor performance, as in Parkin-
son’s disease (PD); however, the extent to which
these symptoms reflect impaired motor learning is
unknown. Here, we demonstrate a D2 receptor
blockade-induced aberrant learning that impedes
future motor performance when dopamine signaling
is restored, an effect diminished by coadministration
of adenosine antagonists during blockade. We
hypothesize that an inappropriate corticostriatal
potentiation in striatopallidal cells of the indirect
pathway underlies aberrant learning. We demon-
strate synaptic potentiation in striatopallidal neurons
induced by D2 blockade and diminished by applica-
tion of an adenosine antagonist, consistent with
behavioral observations. A neurocomputational
model of the basal ganglia recapitulates the behav-
ioral pattern and further links aberrant learning to
plasticity in the indirect pathway. Thus, D2-mediated
aberrant learning may contribute to motor deficits in
PD, suggesting new avenues for the development of
therapeutics.INTRODUCTION
Corticostriatal plasticity has been directly linked to motor
learning and performance (Costa et al., 2004; Yin et al., 2009;
Jin and Costa, 2010). The dorsolateral striatum (posterior puta-
men in primates)—the region most prominently affected in Par-
kinson’s disease (PD) (Bernheimer et al., 1973; Hornykiewicz,
2001)— has been associated with the automization of behavior
(Miyachi et al., 2002; Costa et al., 2004; Poldrack et al., 2005;
Puttemans et al., 2005; Doyon et al., 2009; Yin et al., 2009; JinCell Reand Costa, 2010) and habit (Bernheimer et al., 1973; Hornykie-
wicz, 2001; Tang et al., 2007; Graybiel, 2008; Yin et al., 2009;
Balleine and O’Doherty, 2010), providing a substrate for gener-
ating rapid and efficient behavioral responses without cognitive
deliberation and planning.
Dopamine denervation induces abnormal corticostriatal plas-
ticity (Calabresi et al., 1997; Picconi et al., 2003; Kreitzer and
Malenka, 2007; Shen et al., 2008; Peterson et al., 2012), though
the role this plays in the symptoms, progression, and treatment
of the PD has not been established. We recently proposed that
altered plasticity, specifically inappropriate LTP in striatopallidal
medium-spiny neurons (MSNs), gives rise to an aberrant learning
process that contributes to the symptoms and progression of PD
by inverting basal ganglia optimization of behavior (Wiecki and
Frank, 2010; Beeler, 2011). Computational models suggest an
interaction between dopamine’s effects on MSN activity and
corticostriatal synaptic plasticity—performance and learning,
respectively— within striatal D1- and D2-expressing cells of
the direct and indirect pathways (Frank et al., 2004; Bo´di et al.,
2009; Palminteri et al., 2009; Wiecki and Frank, 2010). To the
degree that the mechanisms of abnormal corticostriatal plas-
ticity are dissociable from those mediating dopamine’s direct
performance effects, they represent a target for novel therapeu-
tics. Remediating abnormal plasticity and aberrant learning may
be a significant but unrecognized component of current drug
therapies and underlie the poorly understood but important
long-duration response (LDR) observed in L-DOPA treatment
(Beeler et al., 2010; Beeler, 2011).
Both the aberrant learning hypothesis and neurocomputa-
tional models point to critical interactive effects between dopa-
mine-mediated performance and learning and make specific
predictions:
(1) Dopamine depletion or receptor blockade, in addition to
direct performance effects, will result in inhibitory learning
in the indirect pathway that will impair future performance
and learning even when dopamine signaling is restored.
(2) In animals that acquired the task under healthy dopa-
mine conditions, dopamine blockade should induce aports 2, 1747–1761, December 27, 2012 ª2012 The Authors 1747
progressive decline in performance, reflecting an aberrant
learning process that will impair future recovery.
(3) If the above effects are due to induction of aberrant poten-
tiation in the D2 pathway, dopamine blockade should
induce potentiation in striatopallidal MSNs that is
reversed by agents known to disrupt LTP in this pathway.
(4) Disrupting LTP in the indirect pathway should be pro-
tective when administered during dopamine blockade
by preventing aberrant learning but impede recovery
when administered after aberrant learning by impairing
relearning.
Here, we test these predictions in a mouse model of motor
learning and concurrently test whether the empirically observed
effects will emerge in an a priori computational model of basal
ganglia function.RESULTS
Blockade of D1 and D2 Signaling Induce Aberrant
Learning Independent of Direct Effects on Performance
To reversibly mimic dopamine denervation, we administered
a cocktail of D1 and D2 dopamine receptor antagonists to block
dopamine signaling in the direct and indirect pathways. The
cocktail was administered either during the initial acquisition or
after the establishment of a striatal-dependent motor skill.
When a dopamine antagonist cocktail is administered during
initial training, the cocktail dramatically impaired rotarod perfor-
mance (treatment main effect, F(1,12) = 34.5, p < 0.001) with no
apparent evidence of learning across the 5 training days (Fig-
ure 1A, left). However, when the mice returned to the rotarod
72 hr after the last cocktail administration, their performance
remains degraded and improves only gradually over 10 days
(Figure 1A, treatment x session interaction, F(1,12) = 23.6, p <
0.001), which contrasts markedly with the 1–2 days required
for naive mice to reach asymptotic performance (Figure 1A,
left; comparing initial 3 days naive versus relearning, treatment
x session interaction, F(1,12) = 11.29, p < 0.01). The dramatically
retarded reacquisition following initial training under cocktail
suggests that an aberrant learning process occurred during the
cocktail training. This was not a residual effect of the cocktail
treatment itself: mice administered the cocktail on the same
schedule as the trainedmice but without rotarod training showed
no impairment in subsequent acquisition (Figure 1A, right),
indicating the diminished performance of cocktail trained mice
is experience dependent.
We further tested if cocktail together with rotarod training
impaired the animals on other tasks. In a new group, we admin-
istered cocktail and provided rotarod training but following the
72 hr break, tested their open field (OF) activity and treadmill
performance instead of rotarod. We compared these mice to
a naive control group and a group administered eticlopride
acutely as a reference for impaired D2 function. Although
decreased D2 activation (i.e., eticlopride) greatly reduces OF
activity, the cocktail/rotarod group does not show decreased
activity (Figure 1C; F(2,18) = 39.12, p < .001). On the first two
days, they show increased activity compared with the naive
mice. The reason for this is unclear but inconsistent with1748 Cell Reports 2, 1747–1761, December 27, 2012 ª2012 The Autdecreased D2 function. Notably, the cocktail/rotarod group
had a week of handling and exercise that may have increased
their comfort level and decreased behavioral inhibition. Consis-
tent with this possibility, they show greater rearing/vertical
time, consistent with greater exploratory behavior (Figure 1D;
F(2,18) = 16.46, p < 0.001). In a second motor performance test,
performance on the treadmill was indistinguishable between
naive and cocktail/rotarod groups, in contrast to greatly reduced
performance as a consequence of reduced D2 signaling (Fig-
ure 1E; group, F(1,22) = 28.3, p < 0.001; naive versus cocktail
trained, F(1,14) = 2.25, p = .15). Together, these data suggest
that the training under D1/D2 blockade resulted in an experi-
ence-dependent aberrant motor learning that task-specifically
impaired subsequent performance and learning.
When the antagonist cocktail was administered after the
motor skill was established (in a separate group of mice), we
observed an aberrant learning effect as well. The cocktail results
in an immediate impairment of performance (treatment main
effect, F(1,10) = 58.7, p < 0.001) but also a further decline across
the initial couple of sessions (Figure 1B, middle; treatment group
only, session effect, F(1,5) = 7.2, p = 0.013). Upon cessation of
cocktail treatment, the mice did not return immediately to their
prior asymptotic performance. Instead, they showed a gradual
return to previous levels of performance (Figure 1B, right; during
recovery phase: prior treatment F(1,10) = 7.2, p = 0.023, prior
treatment x session, F(1,10) = 5.8, p = 0.036). These data suggest
that the cocktail not only impairs performance but when
combined with experience on the motor task, also alters the
underlying learning that supported the previously established
skill, necessitating a relearning phase.
The cocktail blocks both the D1 and D2 receptors. Previous
reports suggest that aberrant learning occurs primarily in the
D2 pathway (Wiecki et al., 2009; Beeler et al., 2010). To indepen-
dently test the contribution of each receptor subtype, we tested
the behavioral consequences of administering eticlopride (D2
selective antagonist) or SCH23390 (D1 selective antagonist),
either during acquisition or after asymptotic performance, as
above.
Blockade of D2 but Not D1 Receptors during Acquisition
Induces Aberrant Learning that Impairs Subsequent
Recovery
Both the D1 and D2 antagonists impair initial acquisition (Figures
2A and 2B, left; acquisition only, treatment effect, F(7,23) = 7.78,
p < 0.001) in a dose-dependent manner (SCH23390 dose,
F(1,18) = 19.87, p < 0.001; eticlopride dose, F(1,13) = 5.39, p <
0.05), though not to the same degree as the cocktail (Figure 1A,
left). At higher doses, D1 and D2 antagonists impaired perfor-
mance to a similar degree. However, a significantly different
pattern of recovery emerged during the drug-free phase de-
pending on whether D1 or D2 receptors were blocked during
acquisition (drug x session during recovery, F(1,25) = 16.09, p <
0.001). Blockade of D1 has a weak effect on subsequent
recovery (Figures 2A and 2C; SCH23390 group during recovery,
dose, F(1,18) = 4.14, p = 0.056). Indeed, we observed an imme-
diate, discontinuous jump to better performance posttreatment
in D1-treated mice with little subsequent improvement (Fig-
ures 2A and 2C; SCH23390 recovery, sessions F(1,18) = 0.79,hors
Figure 1. Dissociating Learning and Performance Effects of Dopamine Receptor Blockade on Acquisition and Maintenance of a Motor Skill
(A and B) To dissociate learning and performance effects, we used a multiphase rotarod design in which initial learning under either a dopamine-normal or
dopamine-impaired condition is paired with a subsequent testing phase in the opposite condition. A two- and three-phase design (shown above graphs) was
used to assess the effects of dopamine-receptor blockade on initial acquisition (two-phase design) or continued performance of an established skill (three-phase
design), respectively. Each daily session consisted of five trials. In all figures, session means averaged across the five trials are reported. Graphs show latency to
fall in wild-type C57BL/6 mice administered either a cocktail of dopamine antagonists (0.16 mg/kg eticlopride + 0.1 mg/kg SCH23390, filled gray triangles) or
saline (filled red circles) during either (A) initial acquisition of rotarod performance or (B) after performance is established through 12 days prior training. A control
group was administered the antagonist cocktail and returned to their homecage without rotarod training and then subsequently tested without drug (A, open gray
squares). Each point represents the mean of five trials during daily sessions. Between each treatment phase, there was a 72 hr break without training.
(C) Distance traveled in the open field (OF) for three 45 min sessions on three consecutive days for a group that previously received cocktail administration and
rotarod training (open triangles), a naive group (red circles), and a group administered 0.16 mg/kg eticlopride 30 min prior to testing.
(D) Average rearing/vertical time across all three OF sessions.
(E) Average percent of time mice (same groups as in D and E) remained in the forward two-thirds of track on treadmill during two 20 s test trials at 15 and 20 cm/s.
(A) n = 7 (homecage controls, open square, n = 5); (B) n = 6; (C and D) n = 7; and (E) n = 8. Error bars, SEM.p = 0.38). For highest doses of D1 blockade during acquisition,
some residual learning appears to have occurred during
recovery (sessions x dose, F(1,18) = 3.37, p = 0.082). In contrast,
D2 blockade during initial acquisition results in poor initial perfor-
mance during recovery and only gradual relearning and improve-
ment (Figures 2B and 2D, right; eticlopride group during
recovery, sessions F(1,13) = 21.4, p < 0.001; dose, not significant
(N.S.); dose x session, F(1,13) = 3.36, p = 0.08). Themild relearning
observed at high doses of D1 blockademay reflect a reduction in
receptor selectivity at higher doses or indicate that sufficient
interference with D1 can also induce mild aberrant learning.
Nonetheless, in general, D1 blockade impaired performance
with minimal effects on subsequent performance, suggesting
a limited role in aberrant learning. In contrast, D2 blockade signif-Cell Reicantly impairs future performance and appears to require
a gradual relearning process. These data suggest that blockade
of D2 induces an aberrant learning during initial acquisition that
delays or hinders subsequent appropriate learning.
When the antagonists are instead applied after asymptotic
performance is established, a difference in the pattern of impair-
ment and recovery emerges. D1 blockade results in an imme-
diate, dose-dependent decrement in performance that is
constant across drug administration sessions (Figures 3A and
3C treatment phase; dose, F(1,18) = 27.1, p < 0.001, session
and dose X session, N.S.). Upon cessation of the antagonist,
performance in mice administered a D1 antagonist returns to
asymptotic performance immediately, showing no dose-depen-
dent effects or relearning (Figures 3A and 3C, recovery phase;ports 2, 1747–1761, December 27, 2012 ª2012 The Authors 1749
Figure 2. Effect of D1 or D2 Antagonism on Acquisition and Subsequent Drug-free Recovery
Latency to fall in wild-type C57BL/6 mice administered an antagonist of either (A) D1 (SCH23390) or (B) D2 (Eticlopride) during 5 days of initial acquisition of
rotarod performance and subsequent nondrug performance. Red traces indicate saline controls (shown in both plots). Bar graphs show the average of the last
3 days of drug training (black bars), followed by the first 5 days of drug-free recovery averaged across all doses for (C) D1 and (D) D2 blockade. Each point
represents the average of five trials during daily sessions. A 72 hr break occurred between treatment and nontreatment phases. n = 4/dose, ***p < 0.001. Error
bars, SEM.dose, F(1,18) = 0.81, p = 0.38, session and dose X session, N.S.).
In contrast, D2 blockade, though it also causes an immediate
performance decrement, also induces gradual deterioration
across treatment sessions (treatment phase, dose main effect,
F(1,14) = 5.9, p < 0.05, dose X session F(1,14) = 6.3, p < 0.05).
During recovery from D2 blockade, unlike D1 blockade, we
observe a continued effect of dose (Figures 3B and 3D, recovery
phase, dose, F(1,14) = 6.29, p < 0.05, session and dose X session,
N.S.) andwhat appears to be amore gradual recovery compared
to recovery fromD1 blockade, though this latter observation was
not statistically significant (drug X session, F(1,15) = 0.77, p =
0.47).
Though D2 blockade during initial acquisition clearly impairs
recovery (Figures 2B and 2D), the degree to which D2 blockade
of an established skill impairs subsequent recovery is less clear
(Figures 3B and 3D). This could arise because putative aberrant
learning may depend on how established the skill is to begin
with. Additionally, the effect of D2 blockade (Figure 3D) does
not appear to titrate as clearly as D1 blockade (Figure 3C); the
lowest dose had no apparent effect (comparing saline and
0.04, dose and dose X session, N.S.) and the 0.16 and 0.64 effect
were similar (comparing 0.16 and 0.64, dose and dose X session,
N.S.). Consequently, we conducted two additional experiments.1750 Cell Reports 2, 1747–1761, December 27, 2012 ª2012 The AutIn the first experiment, we provided a longer initial training
period (12 days, similar to Figure 1B) and directly compare the
effects of D1 and D2 blockade using the doses used in the cock-
tail (Figure 3E). The different treatments yield significantly
different performance effects (treatment, F(1,15) = 13.9, p <
0.001; treatment x session, F(1,15) = 3.68, p < 0.05) and signifi-
cantly different recoveries (recovery, prior treatment effect,
F(1,15) = 9.53, p < 0.01). As observed previously, D1 blockade
results in an immediate decrement that is constant across the
treatment days (SCH23390 treatment effect, F(1,10) = 11.45, p <
0.01; session, N.S.; session x treatment, N.S.), with no effects
on subsequent drug-free recovery (Figure 3E, SCH23390 prior
treatment effect, F(1,10) = 0.124, p = 0.73). In contrast, D2
blockade induces a gradual deterioration across treatment
days (eticlopride treatment effect, F(1,10) = 20.2, p = < 0.01;
treatment x session, F(1,10) = 4.71, p = 0.055) and impaired
performance and slowed recovery during drug-free recovery
(Figure 3E, eticlopride prior treatment effect, F(1,10) = 21.1, p <
0.001; session, F(1,5) = 5.6, p = 0.06).
In the second experiment, we varied the number of training
days prior to administering the D2 blockade (Figure 3F, 12 day
group same as 3E). We observe the same pattern as in Figure 3E
with no significant difference in either treatment or recovery ashors
Figure 3. Effect of D1 or D2 Antagonism on
Established Performance
(A and B) Latency to fall in wild-type C57BL/6 mice
administered an antagonist of either (A) D1
(SCH23390) or (B) D2 (Eticlopride) following 5 days
of initial training under nondrug conditions and
subsequent recovery. Each point represents the
average of five trials during daily sessions.
(C and D) Average performance across sessions
in each phase plotted by dose for (C) D1 and (D)
D2 blockade. Bar graph insets show first three
recovery days averaged across all doses of
SCH23390 and for 0.16 and 0.64 mg/kg eti-
clopride.
(E) Comparison on D1 and D2 blockade
(SCH23390, 0.1mg/kgandeticlorpide, 0.16mg/kg,
respectively) after 12 days of initial training.
(F) Effect of initial training length on subsequent
D2 blockade (eticlopride, 0.16 mg/kg) and
recovery showing 12 (same data as E), 6, and
3 days of training. Throughout, red traces indicate
saline controls. A 72 hr break occurred between
treatment and drug-free recovery phases. n = 4/
dose for (A–D) and n = 6 for (E and F); statistics
reported in text. Error bars, SEM.a consequence of different initial training lengths (treatment
phase, F(1,16) = 3.02, p = 0.1; recovery phase, F(1,16) = 0.53, p =
0.47). The impairment and slow relearning induced subsequent
to D2 blockade during recovery is more apparent with longer
training periods as a consequence of having achieved higher
performance during initial training; however, training under D2
blockade impairs subsequent performance independent of prior
training (recovery, training length, F(1,16) = 0.53, p = 0.47; training
length x session, F(1,16) = 0.06, p = 0.80), suggesting that the
putative aberrant learning that is induced is dependent on expe-
rience during the D2 blockade and not prior skill level.
Together, the data in Figures 2 and 3 show a dissociation
between the immediate, performance degrading effects of
dopamine blockade and the subsequent, drug-free perfor-
mance. These effects on subsequent behavior reflect learning
and, presumably, synaptic plasticity that occurs during training
under the dopamine blockade. Blockade of D1 appears to
primarily induce a performance decrement with immediate
recovery upon cessation of drug. In contrast, D2 blockade
appears to induce an aberrant learning process that results in
persistent impairment and slowed recovery in the drug-free
condition.
We hypothesized that these differential effects of D1 versus D2
blockade could arise as a function of their different effects on
activity and plasticity within the direct and indirect corticostriatalCell Reports 2, 1747–1761, Depathways, respective. Specifically, D1
blockade would reduce striatonigral
MSN activity in the direct ‘‘GO’’ pathway,
associated with selection of the correct
actions, thus impairing performance;
however, this overall decrease in activity
may also protect against aberrant learn-
ing by decreasing the probability ofHebbian plasticity in the first place. In contrast, D2 blockade
enhances excitability of striatopallidal MSNs in the indirect,
‘‘NOGO’’ pathway, increasing inhibitory activity that impairs
performance. In this case, however, the increased activity may
increase the probability of Hebbian plasticity (for review, Wiecki
and Frank, 2010; Beeler, 2011), thus inducing aberrant learning
in the striatopallidal, NOGO pathway.
Adenosine Antagonists Mitigate Aberrant Learning
Although D2 activation is believed to be critical for the induction
of synaptic depression (LTD) in D2-expressing MSNs, activation
of A2A facilitates potentiation at these synapses (LTP) and A2A
blockade prevents this potentiation (Shen et al., 2008; Lovinger,
2010; Peterson et al., 2012). We thus tested the effectiveness of
A2A antagonists in mitigating the deficits induced by dopamine
blockade as described above, by administering adenosine
receptor antagonists during dopamine blockade.
We coadministered an A2A-selective antagonist, SCH58261,
with the dopamine antagonists cocktail during initial acquisition
and tested recovery under drug-free conditions. SCH58261 did
not rescue performance during cocktail administration (Fig-
ure 4A, left; during acquisition, dose, F(1,21) = 0.025, p = 0.87,
dose X session, F(1,21) = 1.34, p = 0.25). Performance during
drug-free recovery, however, differed according to the dose of
SCH58261 coadministered, though only a trend (Figures 4Acember 27, 2012 ª2012 The Authors 1751
Figure 4. Effect of Adenosine Antagonists
on Impairment and Recovery from Dopa-
mine Antagonist Cocktail Administered
during Initial Acquisition
(A) Latency to fall across consecutive days/
sessions for mice coadministered SCH 58261
during cocktail training (red trace, cocktail only;
gray darkens with increasing SCH58261) during
the initial drug treatment phase (TX) and the drug-
free recovery phase (NO TX), with a 72 hr break
between phases.
(B) Summary of dose-dependent effects of
SCH58261 coadministered during initial acquisi-
tion on subsequent drug-free recovery. Mean
latency to fall averaged across sessions during the
drug-free recovery phase plotted by SCH58261
dose (red bar, cocktail only).
(C) Mean latency to fall averaged across all drug-
free recovery sessions showing dose response
for MSX-3 and theophylline coadministered with
dopamine antagonists cocktail during initial
acquisition (red bar, mice administered cocktail
only; darker gray shades represent increasing
doses. MSX-3, 1, 2.5, and 5 mg/kg; SCH58261,
0.6, 1.2, 2.5, 5, and 10 mg/kg; theophylline, 10, 30,
and 60 mg/kg).
(D) Summary of the average latency to fall aver-
aged across doses and sessions during initial
acquisition (black bars) and the subsequent drug-
free recovery (gray bars) for mice coadministered
MSX-3, SCH59261, or theophylline with a cock-
tail of SCH23390 (0.1 mg/kg) and eticlopride
(0.16 mg/kg) during initial acquisition.
(E and F) Latency to fall in wild-type C57BL/6 mice
administered the adenosine antagonist theophyl-
line at the specified dose either (E) during initial
acquisition under a cocktail of dopamine antago-
nists or (F) during the recovery phase subsequent
to initial training under cocktail. Red traces
represent control mice receiving no theophylline.
Each point represents the average of five trials
during daily sessions with a 72 hr break between
phases.
(G and H) Mean performance across sessions
during the recovery phase plotted by theophylline
dose for mice administered theophylline during
either (G) initial training under cocktail or (H) the
recovery phase. n = 4/dose, statistics reported in
text. ***p < 0.001. Error bars, SEM.and 4B; dose, F(1,21) = 3.01, p = 0.09; dose x session, F(1,21) =
1.28, p = 0.27). It is striking that coadministered SCH58261,
despite lack of observable effects during its administration,
appears to improve subsequent performance during the drug-
free recovery phase; however, the response does not appear
to be linearly related to dose (Figure 4B).
We next screened two additional drugs, MSX-3, another
selective A2A antagonist and theophylline, a nonselective
adenosine receptor antagonist. Both drugs coadministered
during training under dopamine antagonists cocktail appear to
improve subsequent drug-free recovery (Figure 4C), though1752 Cell Reports 2, 1747–1761, December 27, 2012 ª2012 The Autonly theophylline is significantly different from cocktail alone
(MSX-3 dose, F(1,14) = 1.65, p = 0.21; theophylline dose,
F(1,14) = 19.65, p < 0.001).
In the remainder of the studies, we use the nonspecific
adenosine antagonist theophylline over SCH58261 for several
reasons. First, although not selective between A1 and A2A,
numerous studies have demonstrated that motor-enhancing
effects of nonselective adenosine antagonists are mediated
through A2A and not A1 (El Yacoubi et al., 2000; Kelsey et al.,
2009; Hsu et al., 2010). Moreover, in a study using 6-OHDA
lesion animalmodels, both the nonspecific adenosine antagonisthors
Figure 5. Effect of Adenosine Antagonist Theophylline on Eticlopride-Induced Aberrant Learning and Recovery of an Established Skill
(A) Latency to fall in wild-type C57BL/6 mice coadministered the A2A antagonist theophylline at the specified dose together with the D2 antagonist eticlopride
(0.16 mg/kg) after initial drug-free training to asymptotic performance (i.e., established skill).
(B) Latency to fall in mice administered either theophylline at 80 mg/kg or saline for 5 days initial acquisition.
(C) Mean latency to fall across sessions during the different phases of the experiment. n = 4/dose, statistics reported in text. Error bars, SEM.caffeine and the A2A-selective SCH58261 enhanced motor
function and L-DOPA efficacy following the lesion, whereas the
A1-selective antagonist CPT did not, again demonstrating that
it is the A2A-specific actions of caffeine (and by extension,
theophylline) that are relevant (Kelsey et al., 2009). Second,
theophylline is a compound that has been in clinical use for
decades, and there is clinical evidence that theophylline has
therapeutic efficacy in PD (Mally and Stone, 1996; Kostic et al.,
1999; Kulisevsky et al., 2002), making it more relevant to poten-
tial clinical studies. Finally, theophylline is water-soluble and
does not require DMSO vehicle. In some cases, we administer
treatments over a period of weeks and wanted to avoid the
potential confound of chronic injections of DMSO. Thus, we
chose theophylline to investigate the amelioration of aberrant
learning.
Theophylline Diminishes Aberrant Learning during
Dopamine Blockade but Impairs Performance when
Administered during Recovery
During initial acquisition, theophylline had little effect on the
performance impairment induced by the D1/D2 antagonist cock-
tail (Figure 4E, left; dose main effect, F(1,22) = 0.90, p = 0.35).
However, during the drug-free recovery phase (neither cocktail
nor theophylline administered), a dose-dependent improvementCell Rein recovery was observed (Figures 4E and 4G; dose main effect,
F(1,22) = 3.4, p < 0.07) similar to that observed with SCH58261
(Figure 4A), suggesting that theophylline diminished the putative
aberrant learning that occurred during acquisition under condi-
tions of dopamine blockade. In contrast, theophylline adminis-
tered during the recovery phase, with the exception of the lowest
dose, impairs recovery (Figure 4F; dose main effect, F(1,22) =
10.4, p < 0.01), showing a dose-response curve that reflects
almost the inverse mirror (Figure 4H) of that observed when
theophylline is administered during acquisition (Figure 4G).
Theophylline Protects Established Skills
We then tested whether theophylline modified the effects of
dopamine receptor blockade on established motor skills by first
training mice to asymptotic performance under normal condi-
tions (i.e., no dopamine manipulation). Then eticlopride was
administered to induce degradation in performance and putative
aberrant learning (as in Figures 3B, 3E, and 3F), either with or
without coadministration of theophylline. In mice that received
only eticlopride, we observe the same gradual deterioration in
performance and gradual recovery observed above (Figure 5A).
In contrast, in mice that received coadministered theophylline,
the performance impairment induced by D2 blockade did not
show gradual deterioration but rather an immediate decrementports 2, 1747–1761, December 27, 2012 ª2012 The Authors 1753
that remained constant across sessions (Figure 5A; during treat-
ment, all groups, session x dose, F(1,22) = 13.1, p < 0.01; each
group separately, session was only significant for eticlopride-
only group, F(1,4) = 12.33, p = 0.039, all theophylline doses,
session N.S.). Critically, upon discontinuation of the eticlopride
and theophylline, the mice that had received theophylline
showed no subsequent impairment in performance (Figures 5A
and 5C; dose main effect on recovery, all groups, F(1,22) = 8.18,
p < 0.01; theophylline treated only, F(1,17) = 1.58, p = 0.227), indi-
cating that theophylline, though not eliminating the direct perfor-
mance impairment induced by eticlopride, did effectively block
aberrant learning protecting established skills.
Adenosine Antagonism Has No Effect on Initial
Acquisition under Normal Conditions
When applied during initial acquisition without dopamine
blockade, theophylline has no effect on learning and perfor-
mance (Figure 5B). These data suggest that a potential reduction
in striatopallidal LTP arising from A2A blockade does not impair
initial acquisition. Learning in the striatonigral pathway may
compensate for reduced LTP in the indirect pathway in de
novo learning; however, once aberrant learning is established,
a full range of plasticity is apparently required to ‘‘unlearn’’ it
and implement appropriate learning.
D2 Blockade Induces Potentiation in Striatopallidal
MSNs that Is Diminished by Theophylline
Corticostriatal LTD, believed to be critical for behavior andmotor
execution, is facilitated by activation of D2 receptors (Gerdeman
et al., 2002; Calabresi et al., 2007; Kreitzer and Malenka, 2008;
Shen et al., 2008; Lovinger, 2010). Loss of D2 activation, such
as occurs with dopamine denervation or depletion, blocks
high-frequency stimulation-induced LTD (Calabresi et al., 1997;
Gerdeman et al., 2002; Kreitzer and Malenka, 2007; Bagetta
et al., 2011). However, increasing evidence suggests that dopa-
mine denervation not only impairs LTD but inverts it such that
conditions that would normally induce LTD (i.e., high-frequency
stimulation or spike-timing dependent LTD) instead induce LTP
(Calabresi et al., 1997; Picconi et al., 2003; Shen et al., 2008;
Peterson et al., 2012). These studies provide compelling
evidence that loss of dopamine signaling at D2 receptors can
invert corticostriatal plasticity in the striatopalidal pathway,
which we propose underlies aberrant learning. Therefore, we
tested the effects of D2 blockade on the strength of excitatory
cortical inputs to stratopallidal MSNs.
In the presence of bath-applied sulpride (20 mM), we observed
a gradual increase in the strength of glutamatergic input to D2-
expressing MSNs, without any stimulation protocol (Figures 6B
and 6C). As the measurement of EPSCs itself constitutes
a low-frequency stimulation, for a subset of cells we withheld
stimulation for 10 min during the sulpiride administration and
applied two doses of sulpiride, 2 and 20 mM. In this subset of
cells, we observe dose-dependent potentiation in the absence
of any exogenously applied stimulation (Figure 6D). Previous
reports demonstrate that LTP in the striatopallidal pathway is
facilitated by activation of the A2A adenosine receptor and can
be blocked by A2A antagonism (Schiffmann et al., 2003; Shen
et al., 2008; Peterson et al., 2012). We then tested whether D21754 Cell Reports 2, 1747–1761, December 27, 2012 ª2012 The Autblockade-induced potentiation is sensitive to A2A antagonism.
Bath application of theophylline (1 mM) in combination with
sulpiride reduced the potentiation seen with sulpiride alone
(Figures 6B and 6C).
These data suggest that D2 blockade induces potentiation in
striatopallidal MSNs, a process that may contribute to the
increased responsiveness observed in indirect pathway MSNs
after dopamine denervation (Mallet et al., 2005; Gertler et al.,
2008; Peterson et al., 2012). These data are consistent with
previous reports showing that dopamine denervation or loss of
D2 signaling can induce LTP instead of LTD (Calabresi et al.,
1997; Picconi et al., 2003; Shen et al., 2008; Peterson et al.,
2012), suggesting that dopamine denervation and subsequent
decreases in D2 signaling favor LTP in the corticostriatal
synapses in the indirect pathway and increase inhibitory tone-
modulating cortical activity. Enhanced excitatory drive onto
striatopalidal MSNs under these conditions is consistent with
the proposed mechanism underlying the aberrant learning
observed behaviorally. The decrease in D2 blockade-induced
potentiation observed with application of theophylline, together
with reports that A2A antagonism can impede striatopallidal
potentiation (Schiffmann et al., 2003; Shen et al., 2008; Peterson
et al., 2012), is a likely explanation for the partial protection from
aberrant learning observed in our behavioral studies.
Modeling Rotarod Skill Learning
Adapting a previously published basal ganglia (BG) model
(Frank, 2005; Wiecki et al., 2009), we simulated the demands
of the rotarod task by assuming that the mice have to select
between four possible motor outputs (R1–R4, e.g., which paw
to move forward), depending on the sensory state. Motor
tasks like the rotarod are dynamic and integrative such that
the correct action needed in response to a particular sensory
state (e.g., position on the rod) may depend on the identity
of another variable (e.g., proprioceptive input). We simulated
this type of task by including two sets of inputs, each having
two possible stimuli (i.e., SA1, SA2; SB1, SB2). The ‘‘correct’’ motor
actions (i.e., those that would prevent the animal from falling
off the rod) were dependent on conjunctive combinations of
the two sets. For example, if SA1 is present, then SB1 should
be associated with R1 and SB2 with R2. If SA2 is present, then
SB1 should be associated with R3 and SB2 with R4. We
adopted this input-output structure to capture the integrative
stimulus-response learning attributed to the dorsal striatum.
The different sets of inputs to be integrated could potentially
represent context and discrete stimuli, information from dif-
ferent sensory modalities (visual, proprioceptive, vestibular),
different coordinate systems (e.g., position on rod as medial/
lateral and forward/backward) and so on. The requirement to
integrate on-going stimuli to determine a complex state and
the appropriate response more realistically reflects the sensori-
motor integration required in the rotarod task. To simulate the
acceleration of the rotarod, we restricted the amount of time
that the model had to select a response such that with each
correct action the time limit was decreased. The model is
described briefly in Figure 7 (schematic), and detailed descrip-
tion and equations are provided in the Extended Experimental
Procedures.hors
Figure 6. D2 Blockade Potentiates Excitatory Inputs to Striatopallidal MSNs, which Is Reduced by Theophylline
(A) D2-GFP medium spiny neurons in the dorsolateral striatum were held in voltage clamp (Vm,70 mV; Rec, recording electrode). Stimulating electrodes (Stim)
were placed near the corpus callosum, which allowed stimulation of corticostriatal evoked excitatory synaptic currents (EPSCs) at 30 s intervals.
(B) After baseline EPSC amplitude was established, bath application of the D2 receptor antagonist sulpiride potentiated evoked EPSC’s (20 mM; filled symbols;
n = 4). Coapplication of the adenosine antagonist theophylline (1 mM) significantly attenuated the effects of sulpiride on EPSC amplitude (open symbols; n = 6).
(C) Example traces from each recording condition.
(D) In a separate set of experiments, bath application of sulpiride still potentiated evoked EPSC’s in the absence of any stimulation (solid symbols, n = 5). Similar
effects were observed with administration of 2 mM sulpiride (open symbols, n = 3). *p < 0.05. Error bars, SEM.Modeling Dopamine Effects on Performance and
Learning
Dopamine modulates the balance of activity and plasticity in the
direct (GO) and indirect (NOGO) pathways. Increased dopamine
excites the D1-expressing GO pathway and inhibits the D2-
expressing NOGO pathway, whereas decreased dopamine has
the opposite effect. Dopamine also modulates learning.
Following a correct response, phasic increases modulate plas-
ticity differently in the direct, striatonigral GO and the indirect,
striatopallidal NOGO pathways. Increased phasic dopamine
activates D1 and D2, increasing (LTP) and decreasing (LTD)
synaptic weights in the direct and indirect pathways, respec-
tively, in proportion to their activity, thereby facilitating (GO
LTP) and disinhibiting (NOGO LTD) that response in future
presentations of the same stimuli. The net effect is to drive
activity-dependent plasticity so that weights from the activeCell Reinputs to GO units associated with rewarding actions are
increased, while diminishing the NOGO activity associated with
those same inputs. When the network selects an erroneous
response, phasic dips of dopamine induce the reverse learning
process such that the weights in the indirect, striatopallidal
NOGO pathway are strengthened (LTP), reducing the likelihood
of repeating the error in the future.
These performance and learning effects are interactive. For
example, D2 blockade enhances the excitability of NOGO units
and hence their propensity for activity-dependent plasticity.
This effect manifests itself such that even if adaptive actions
are selected, the greater NOGOactivity arising fromD2blockade
drives inhibitory learning in response to the current sensory
states but does so as if there had been a dip in phasic dopamine
activity. Thus, even after D2 blockade is removed, NOGO activity
is associated with correct responses and impairs performance.ports 2, 1747–1761, December 27, 2012 ª2012 The Authors 1755
Figure 7. Model Performance under Conditions Recapitulating Mouse Experiments
(A) Shows the percentage of correct responses by the model intact (open red symbols) and with dopamine blockade (filled gray triangles) and subsequent
recovery with dopamine activity restored (open gray triangles). Each point represents the average of four trials.
(B) Shows the effect of blocking either the D1/GO layer (filled triangles) or the D2/NOGO layer (filled squares) subsequent to initial intact learning and subsequent
recovery when dopamine function is restored (open symbols).
(C) Themodel was trained under dopamine blockade with a reduced learning rate in the D2/NOGO layer (learning set to one-half, light gray, set to zero, dark gray)
to simulate A2A antagonism, either during initial acquisition under dopamine blockade (triangles) or during dopamine-restored recovery (squares).
(D) Initial model learning and performance under normal dopamine function with (gray symbols) andwithout (red symbols) D2/NOGO learning rate reduced to zero
to simulate A2A antagonism.
(E) Bar graph showing average performance across epochs during the recovery phase grouped by time (during acquisition or recovery) and degree of reduction in
D2/NOGO learning rate (i.e., ‘‘theophylline’’).
Schematic of basal ganglia neurocomputational model. The basal ganglia model includes layers incorporating the direct (GO) and indirect (NOGO) pathways from
cortex (two input layers) through the striatum (GO and NOGO units), to the globus pallidus externa (GPe), the substantia nigra reticulata/globus pallidus interna
(GPi), the thalamus, the premotor cortex (PMC) to the output, or motor cortex. SNc dopamine neurons project to both the GO and NOGO layers of the striatum
simulating projections to D1 and D2 MSNs (GO/NOGO, respectively, see the Extended Experimental Procedures for a detailed description). Fast-spiking
inhibitory interneurons (data not shown) regulate activity in both striatal populations via feed-forward inhibition. At each trial, the network is presented input from
each of two input layers (raised cylinders represent example unit activity). Premotor cortical (PMC) units representing the four candidate responses then become
noisily activated. Under baseline conditions, the thalamus is inhibited, but a response is selected once a thalamic unit becomes disinhibited and amplifies activity
in the correspondingmotor units. The role of the BG is tomodulate activity in the thalamus according to whether the responses are adaptive in the current sensory
state. Each phase of the experiment (i.e., analogous to with or without administered drugs, as in the mouse studies) consisted of 20 epochs, equivalent to
sessions. Each epoch contained four trials. Model performance is reported as a percentage of correct responses. Each data point is the average performance of
20 models initialized with different random weights (i.e., n = 20). Error bars, SEM.
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Simulating Pharmacological Manipulations
Pharmacological blockade of D1 or D2 were directly and inde-
pendently mimicked in the model by reducing the efficacy with
which dopamine modulates the excitatory D1-GO projections
or the inhibitory D2-NOGO projections to approximately 65%
of the intact values (Extended Experimental Procedures). As
the partial protection against aberrant learning observed above
is hypothesized to arise from an A2A blockade that diminishes
plasticity in the indirect, D2-expressing pathway, we examined
whether the effects of theophylline could be recapitulated
solely by reducing or eliminating plasticity in the corticostriatal
projections to D2 units. The model then tests whether plasticity
in the indirect pathway alone can account for the behavioral
findings.
Model Recapitulates Effects of Dopamine Blockade on
Learning and Performance
Figure 7A shows that the intact model can robustly learn the
conjunctive associations and select correct actions R1–R4. As
expected, simulated D1/D2 blockade results in the same severe
performance deficit observed in the mouse studies (Figure 7A,
left). However, we hypothesized that it would also drive aberrant
learning as described above. Indeed, upon removal of the
blockade, recovery is gradual (slower than that for intact models
during initial acquisition) and does not fully recover (Figure 7A,
middle).
We next examined whether the model can account for perfor-
mance if dopamine blockade is applied after asymptotic perfor-
mance, independently for D1 and D2 receptors (Figure 7B). We
observed that initial application of D2 blockade after learning
was associated with relatively preserved motor performance
that then gradually declined, as observed with mice. With D1
blockade, there is less impairment and, unlike in the mice, it
does show a small gradual decline, though not as pronounced
as D2 blockade. However, upon removal of D1 blockade, perfor-
mance returned immediately to prior asymptotic levels, whereas
with D2 blockade a gradual relearning was required, consistent
with behavioral observations.
The model recapitulates the pharmacological data because
D2 blockade enhances activity in the NOGO units and induces
synaptic potentiation (LTP) even following correct responses
that would normally induce depression (LTD), driving aberrant
learning. Once indirect pathway inhibition has been learned
through inappropriate LTP, it needs to be unlearned for recovery
to occur even when dopamine is restored. In contrast, D1
blockade, although it prevents the network from selecting the
correct response due to reduced facilitation from GO units,
does not significantly induce an aberrant learning process
because D1 blockade reduces activity and lowers the propensity
for activity-dependent plasticity, thus minimizing aberrant
learning. Thus, in contrast to D2 blockade, removal of D1
blockade allows the network to express its previously learned
adaptive weights.
Can Blocking Plasticity in the D2 Pathway Mimic
Theophylline Administration?
Finally, we tested whether plasticity in the indirect, NOGO
pathway can account for the differential effects of theophyllineCell Rewhen the drug is applied during acquisition or recovery. Specif-
ically, as A2A antagonism can diminish striatopallidal LTP under
at least some conditions (Schiffmann et al., 2003; Shen et al.,
2008; Peterson et al., 2012), we modeled theophylline as a
reduction of plasticity in the striatopallidal NOGO units.
Consistent with behavioral observations, simulated A2A
antagonism (blocking corticostriatal NOGO plasticity) during
initial acquisition did not rescue performance during simulta-
neous dopamine blockade (Figure 7C, left). However, blockade
of NOGO plasticity did improve subsequent recovery when
dopamine blockade was removed, reducing aberrant learning
(Figures 7C and 7E). Moreover, subsequent recovery speed
was now in the same range as that of intact models during initial
learning (compare with previous Figure 7A) and better than
recovery without NOGO blockade of plasticity (Figure 7C).
In the mouse studies, theophylline applied during the recovery
phase rather than during acquisition impaired rather than
improved recovery. The same effect was observed in the model
(Figures 7C and 7E). Reducing or blocking plasticity in the NOGO
pathway during recovery impairs the model’s ability to (1) learn
which actions should be suppressed because they are maladap-
tive and (2) ‘‘unlearn’’ inhibitory, NOGO weights inappropriately
associated with correct actions. Finally, as with the mice, block-
ing plasticity in the NOGO pathway had little effect during initial
acquisition under normal conditions (i.e., no dopamine blockade,
Figure 7D), suggesting in the naive state, correct stimulus-action
associations can be learned in the GO pathway, suggesting that
aberrant learning and plasticity in the indirect pathway (i.e., inap-
propriate LTP) is more deleterious than a simple deficit of
plasticity.
Unlike experiments with animals and humans, where it is
difficult to isolate potential mechanisms and substrates, in a
computational model we have complete control. Using an a
priori model of the basal ganglia that has been applied to various
human and animal data sets, we show here that the aberrant
learning observed in mice can be accounted for specifically by
alterations in plasticity in the indirect, striatopallidal pathway.
As this model was neither developed specifically for these
studies nor to test the aberrant learning hypothesis, it is notable
that the model recapitulates so closely the array of behavioral
phenomena observed.
DISCUSSION
Corticostiatal throughput is modulated through two main path-
ways. Activity in the D1-expressing direct, striatonigral ‘‘GO’’
pathway favors disinhibition of cortical activity and facilitates
behavioral throughput. Activity in the D2-expressing, indirect
striatopallidal ‘‘NOGO’’ pathway, in contrast, favors inhibition
of cortical activity and inhibits behavioral throughput (Albin
et al., 1989; Alexander et al., 1990; Mink, 1996). Dopamine shifts
the balance between these two pathways such that increased
dopamine increases the responsiveness of the GO pathway via
D1 activation, while simultaneously decreasing the influence of
the NOGO pathway via activation of D2. Conversely, diminished
dopamine will favor the inhibitory NOGO pathway because of
greater activity in D2-expressing MSNs as a consequence of
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model in controlling motor performance in rodents (Hikida et al.,
2010; Kravitz et al., 2010).
Dopamine also modulates corticostiatal plasticity (Calabresi
et al., 1992a, 1992b; Kreitzer and Malenka, 2008; Surmeier
et al., 2009; Wickens, 2009; Lovinger, 2010) in both the striato-
nigral GO and striatopallidal NOGOpathways, further influencing
motor performance through learning. Corticostriatal plasticity
can enhance or diminish the responsiveness of either pathway
to cortical input, selectively facilitating the expression or inhibi-
tion of specific responses and motor skills. Our previous studies
suggest that this adaptive plasticity is altered in the D2 pathway
under conditions of dopamine depletion, blockade, or denerva-
tion (Wiecki et al., 2009; Beeler et al., 2010; Wiecki and Frank,
2010; Beeler, 2011), giving rise to an aberrant learning that
selectively encodes inappropriate inhibition through experi-
ence-dependent synaptic changes that impede future motor
responses even if dopamine is restored (i.e., such as in L-
DOPA treatment).
We propose that the mechanism that underlies aberrant
learning is altered corticostriatal plasticity in the indirect, striato-
pallidal pathway that favors synaptic potentiation (LTP) at
the expense of synaptic depression (LTD), inappropriately
increasing the responsiveness of striatopallidal MSNs to cortical
input and pathologically increasing behavioral inhibition. Sub-
stantial evidence supports this proposed mechanism. In mice
lacking D2 receptors, the same high-frequency stimulation
protocol (HFS) that induces LTD instead induces LTP (Calabresi
et al., 1997). In 6-OHDA lesioned rats, a model of PD, HFS also
induces LTP rather than the normal LTD (Picconi et al., 2003),
though Kreitzer and Malenka (Kreitzer and Malenka, 2007) in
a similar study observed only a loss of LTD and not its inversion
to LTP. The reason for this discrepancy is unclear, though subse-
quent reports confirm the inversion of plasticity under dopamine
denervation and further suggest the abnormal LTP is dependent
upon A2A activation (Shen et al., 2008; Peterson et al., 2012).
Here, we show that in the absence of HFS, D2 blockade induces
potentiation in striatopallidal synapses that is diminished by
administration of an adenosine antagonist that blocks A2A,
consistentwith recent studies andwith theobservedameliorative
effects of theophylline administered during dopamine blockade.
Taken together, the present data and published studies strongly
support the hypothesis that D2 blockade (and dopamine dener-
vation/depletion) shift striatopallidal plasticity to inappropriately
favor LTP. By favoring and increasing synaptic potentiation at
the expense of depression, dopamine blockade/denervation
increases the learned responsiveness of striatopallidal neurons
to afferent input, consequently enhancing inhibitory tone on
cortical activity, asproposed tounderlie aberrant learning (Wiecki
et al., 2009; Beeler, 2011). In short, dopamine denervation is
widely believed to induce an imbalance between the direct
and indirect pathways; here, we suggest that altered cortico-
striatal plasticity contributes a learned component to this imbal-
ance: inappropriate inhibition structurally embedded as physical
changes in synapses. Importantly, though pharmacological
treatment may both reverse the imbalanace in activity between
the direct and indirect pathways and restore normal plasticity,
structural changes arising from aberrant learning can only be
reversed through further structural changes, that is, relearning.1758 Cell Reports 2, 1747–1761, December 27, 2012 ª2012 The AutWe attribute the partial protection against aberrant learning
afforded by theophylline to its actions on postsynaptic A2A
receptors. Though theophylline is a nonselective adenosine
antagonist, several studies have demonstrated that the motor-
improving effects of nonselective adenosine antagonists are
mediated through their actions on A2A; A2A- but not A1-
selective compounds yield the same results (El Yacoubi et al.,
2000; Kelsey et al., 2009; Hsu et al., 2010). Moreover, published
studies have demonstrated that A2A blockade can decrease
potentiation in striatopallidal MSNs (Shen et al., 2008; Peterson
et al., 2012), consistent with the electrophysiological data
obtained here. As A2A is expressed both postsynaptically on
striatopallidal MSNs, as well as presynaptically on glutama-
tergic terminals, it is possible that the effects of theophylline,
even on A2A receptors, is mediated pre- rather than postsynap-
tically. Indeed, Calabresi and colleagues have demonstrated
that A2A antagonist (though notably only in combination with
D2 agonist) can reduce glutamatergic transmission through
a presynaptic mechanism (Tozzi et al., 2007); however, Quiroz
et al. (2009) have shown that the A2A receptor is expressed
presynaptically only on cortical afferents synapsing on striato-
nigral MSNs, suggesting that effects of A2A antagonist on
striatopallidal cells will bemediated exclusively through postsyn-
aptic A2A receptors. Finally, the model suggests that reducing
synaptic plasticity in the striatopallidal pathway can account
for and recapitulate the theophylline effects, further supporting
a striatopallidal, postsynaptic mechanism underlying the partial
protection from aberrant learning conferred by theophylline.
Nonetheless, it should be borne in mind that theophylline is not
A2A selective, leaving open the possibility that other actions in
addition to A2A antagonism may contribute to its ameliorative
effects.
The pharmacological model used here captures one aspect of
PD, the reduction in activation of D1 and D2 that occurs as
a consequence of denervation. The simplicity of the model, the
reversibility of pharmacological blockade together with ability
to block D1 and D2 individually represents strengths that
facilitated the present studies, which would have been intrac-
table in the more traditional 6-OHDA model of PD. We show
that impaired dopamine signaling induces aberrant learning.
By necessity, our model induces acute, temporary decreases
in dopamine signaling. The role such aberrant learning plays in
PD is likely to be complex and complicated by adaptation to
chronic denervation; however, in a previous study using PITx3-
deficient mice that exhibit a 90% loss of dopamine denerva-
tion in the dorsal striatum from birth and show physiological
adaptations characteristic of PD, we observe a similar aberrant
learning (Beeler et al., 2010). We have advanced the hypothesis
that the poorly understood long-duration response (LDR) to
L-DOPA (Muenter and Tyce, 1971; Anderson and Nutt, 2011)
arises as a correction of aberrant learning (Beeler et al., 2010;
Beeler, 2011). In this view, under progressive dopamine dener-
vation, patients take a ‘‘double hit’’ in that declining dopamine
induces direct motor performance deterioration but also through
abnormal corticostriatal plasticity and aberrant learning,
unravels previously established learning, essentially inverting it
to favor inhibition rather than facilitation of movement. The
short-duration response (SDR) of L-DOPA then reflects thehors
correction of direct motor performance deficits induced by
dopamine depletion and lasts only as long as L-DOPA is present
(Nutt et al., 1997). In contrast, by correcting underlying abnormal
corticostriatal plasticity, L-DOPA restores normal learning and
skill building. This corrective aspect of L-DOPA treatment is
cumulative and retained as the appropriate calibration of millions
of synaptic strengths that endures during trough periods of
medication—or even on discontinuation of treatment, until aber-
rant learning reverses this learning and inappropriate synaptic
strengths again predominate.
This view suggests an alternative therapeutic strategy of tar-
geting pathways that mediate abnormal corticostriatal plasticity
in the D2-expressing, indirect pathway; in essence, seeking to
effect an LDR-like therapeutic independent of an SDR-like effect.
The theophylline studies described here suggest this strategy
may be feasible. Theophylline improved recovery in a dose-
dependent manner when administered during putative aberrant
learning under dopamine blockade, suggesting this interven-
tion partially mitigated aberrant learning. In contrast, when
administered subsequent to aberrant learning, it did not facilitate
performance; indeed, at most doses it appeared to slow
recovery. These data would suggest that A2A antagonists are
likely to have limited therapeutic efficacy in ameliorating the
direct effects of dopamine denervation on performance, that
is, limited SDR-like actions. However, A2A antagonists may
mitigate underlying abnormal corticostriatal plasticity in the
D2-expressing indirect pathway and diminish aberrant learning,
as observed here, inducing an LDR-like therapeutic efficacy.
Importantly, from a clinical perspective, the A2A antagonism
had no effect on learning under normal conditions (i.e., without
prior aberrant learning). These observations may suggest alter-
native perspectives on the clinical potential of A2A antagonists,
including their use early in the disease process to preserve
established skills and slow aberrant learning, though more
investigation is necessary.
The present observations have implications for rehabilitative
approaches to treating PD (Abbruzzese et al., 2009; Keus
et al., 2009; Nieuwboer et al., 2009). Rehabilitation protocols
are, at their core, based on repetition and practice. If dopamine
depletion induces experience-dependent aberrant learning, then
it is possible that skill practice during lowmedication states (e.g.,
medication troughs, drug holidays) might degrade rather than
improvemotor skills. In contrast, skill practice during peak medi-
cation, when normal corticostriatal plasticity and learning are
restored, would facilitate optimal performance gains. In short,
rehabilitative treatments may potentially enhance or diminish
the LDR of L-DOPA treatment, depending upon when they are
administered. The ‘‘use it or lose it’’ strategy (Archer et al.,
2011) may depend critically on timing.
Evidence suggests that aberrant learning may precede frank
motor symptoms of PD (see Beeler, 2011 for review). Because
different territories of the striatum are differentially affected as
denervation progresses, it is possible that a process of denerva-
tion/ aberrant learning/ compensation/ failure of compen-
sation is recapitulated across striatal territories at different time
courses. Thus, aberrant learning may play an important role in
the development of cognitive impairments in PD (Wiecki and
Frank, 2010). Consequently, an ‘‘LDR-like’’ treatment targetingCell Reaberrant learning may be useful in ameliorating or delaying the
development of cognitive symptoms.
EXPERIMENTAL PROCEDURES
Animals
Mice were housed in standard conditions on a 06:00 to 18:00 light cycle with
ad libitum food and water. Experiments were carried out during the light
cycle. Animal procedures were approved by the Institutional Animal Care
and Use Committee at the University of Chicago. All mice were C57BL/6
wild-type mice between 8–12 weeks of age. For the in vitro electrophysiology,
adult (4- to 12-week-old) transgenic mice hemizygous for Drd2-enhanced
green fluorescent protein (EGFP) bacterial artificial chromosome (BAC) of
both sexes were used in all experiments. Drd2-EGFP homozygotes were iden-
tified from test crosses and then crossed with C57BLK6 mice to produce
hemizygotes.
Behavior Tests
A computer-controlled rotarod apparatus (Rotamex-5, Columbus Instru-
ments, Columbus, OH, USA) with a rat rod (7 cm diameter) was set to accel-
erate from 4 to 40 revolutions per minute rpm) over 300 s, and recorded
time to fall. Mice received five consecutive trials per session, one session
per day (30 s between trials). Open field chambers were 40 3 40 cm (Med
Associates, St. Albans, VT, USA) with lighting at 21 lux. Infrared beams re-
corded the animals’ locomotor activity and rearing movements (vertical
activity). Data were collected in 5 min bins during 45 min sessions for
3 days. For the treadmill performance, a plexiglass enclosure was placed
over the treadmill to force the mice to remain on the track during the trials
(enclosed treadmill space, 5 3 20 cm). Mice were provided three 20 s trials
per day for 3 days at incrementing speeds (10, 15, and 20; 15, 15, and 20;
15, 20, and 20 cm/s, days 1–3, respectively). Their performance was assessed
on the final day at 15 and 20 cm/s by recording the amount of time the animals
remained in the forward two-thirds of the track versus falling back into the
back third.
Drug Administration
All injections were intraperitoneal (i.p.) at 0.01 ml/g of body weight. SCH23390,
eticlopride, and theophylline (Sigma-Aldrich, St. Louis, MO, USA) were
administered 30 min prior to sessions at the specified doses prepared in
0.9% saline.
In Vitro Electrophysiology
After isoflurane anesthesia, animals were decapitated, and their brains
removed to ice-cold sucrose aCSF (in mM: sucrose 125, KCl 2.5, MgCl2 1,
CaCl2 2.5, glucose 20, NaH2PO4 1, NaHCO3 25, ascorbic acid 10; bubbled
with 95%O2/5%CO2). Coronal slices were cut (250 mM; VT1000S, Leica) con-
taining the dorsolateral striatum (+0.4 mm-+1.0 mm from bregma) and
removed to a holding chamber perfused with normal aCSF (in mM: NaCl
125, KCl 2.5, MgCl2 1, CaCl2 2.5, glucose 20, NaH2PO4 1, NaHCO3 25, ascor-
bic acid 1; bubbled with 95% O2/5% CO2), 20 ml/min at 34C. For recording,
the slices were superfused with normal aCSF without ascorbic acid at 2 ml/
min, 32C. In the dorsolateral striatum D2-GFP MSN’s were visualized using
fluorescence illumination on an upright microscope (Axioskop, Zeiss, Oberko-
chen, Germany). Whole-cell voltage clamp recordings used an Axopatch 200B
amplifier, a Digidata 1200 interface, and pCLAMP 8 (Molecular Devices,
Sunnyvale, CA, USA). All recordings were filtered at 1 kHz and digitized at
5kHz, Vm = 70 mV. For all recordings we used borosilicate electrodes (3–7
MU) containing (in mM), K-gluconate 154, KCl 1, EGTA 1, HEPES 10, glucose
10, and ATP 5 (pH 7.4 with KOH). Only cells with series resistance <20 MU
were included. For stimulation of corticostriatal inputs, a bipolar tungsten
electrode with a 500 mm tip separation was placed inside the cortical border
of the dorsolateral striatum. After establishing a consistently evoked EPSC
amplitude once every 30 s for 5 min, sulpiride (20 mM) was bath applied either
on its own or with theophylline (1 mM). Recording was continued in the pres-
ence of drug for a further 15–20 min after which most of the recordings were
terminated. Sulpiride and theophylline were purchased from Sigma-Aldrich.ports 2, 1747–1761, December 27, 2012 ª2012 The Authors 1759
Statistical Analysis
Behavior
In all rotarod studies, the data were tested for significance using ANOVA (R
statistical software [R version 2.12.1 2010-12-16] The R Foundation for Statis-
tical Computing; http://www.r-project.org). Dose effects were modeled as
continuous; comparison between drugs (including drug/dose comparisons)
were modeled as factors with a level for either each drug or each drug/dose
combination. As we used repeated-measures (five trials/session, multiple
sessions across experiment), session was always included as a continuous
independent variable with an error term of mouse/session for repeated-
measures, for example,
statistics= aovðlatency  drug  session+Errorðmouse=sessionÞÞ:
Electrophysiology
All data are reported asmean ± SEM and expressed as the normalized value of
the baseline (5 min) before drug application. For analysis of drug effects on
EPSC amplitude we used a two-way repeated-measures ANOVA, followed
by a Tukey post hoc test on the EPSC amplitudes collected 5 min before
drug exposure and 15–20 min after that time. Statistical significance was
determined by p < 0.05; all statistical tests were performed using Sigmastat
(Systat software).
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